Clinical characteristics and associated factors in patients with statins induced liver injury

Abstract

Abstract: Objective To investigate the characteristics of patients with statins-induced liver injury.Methods Twenty-six patients with statins-induced liver injury were enrolled, and age, sex, liver disease history, clinical manifestations, laboratory index, drugs, treatments, etc. were retrospectively analyzed.Results Among all the patients, 19 were female and 7 were male. Clinical manifestations included poor appetite, fatigue, yellow urine and so on. Hepatocellular type was the predominant type in these cases. Five kinds of drugs were involved, mainly including simvastatin, atorvastatin, and rosuvastatin.Conclusion Patients with statins-induced liver injury had various clinical manifestations with comparatively good prognosis.

Key words: Statins, Drug-induced liver injury

CHEN Bu-kuan. Clinical characteristics and associated factors in patients with statins induced liver injury[J]. Chinese Hepatolgy, 2017, 22(10): 885-887.

References

[1] 崔志敏,赵佳钧,任丽楠,等.药物性肝损害213例临床特点及诊治体会.现代消化及介入治疗,2014,19:104-107.
[2] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南.临床肝胆病杂志,2015,31:1752-1769.
[3] 陈成伟.药物性肝损害诊断标准的演变和评价.中国临床医生,2011,39:68-71.
[4] Chalasani NP, Hayashi PH, Bonkovasky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterology, 2014, 109:950-966.
[5] Gao H, Li N, Wang JY, et al. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. J Dig Dis, 2012,13:33-39.
[6] Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol, 2014, 4 :332-346.
[7] 李俊,黄邵萍,陆基华,等.药物性肝损伤临床特点及致病药物回顾性分析.胃肠病学和肝病学杂志,2016,225: 164-167.
[8] Soldin OP, Chung SH, Mattison DR. Sex differences in drug disposition. J Biomed Biotechnol,2011,2011:187103.
[9] 邓华,雷招宝.他汀类药物引起的肝损害.药物不良反应杂志,2012,14,2:88-92.
[10] 吕剑敏,程锐,吴伟东.导致药物性肝损害的相关因素分析及针对性干预措施.世界华人消化杂志,2014,22:409-414.
[11] 张清,赵英明,陈波,等.他汀对既往有乙肝病毒感染时患者肝损害的影响.中国介入心脏病学杂志,2011,19:223-226.
[12] 赵兰兰,张玉.药物性肝损伤的风险评估及诊治进展.国际消化病杂志,2015,35:119-121.
[13] Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology, 2008, 135:1-4.
[14] 徐兴仙,徐爱建,徐德政.阿托伐他汀与瑞舒伐他汀对冠心病患者肝功能影响的对比.中国药师,2015,18: 255-257.
[15] Alla V,Abraham J,Siddiqui J,et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterolgy,2006,40: 757-761.
[16] Minha S,Golzman G,Adar I,et al.Cholestatic jaundice induced by atorvastatin: a possible association with antimitochondrial antibodies. Isr Med Assoc J,2009,11: 440-441.
[17] 石文斌,丁宇杉,庞莉莉,等.瑞舒伐他汀钙致急性肝功能损害1例.药物流行病学杂志, 2013, 22: 339-340.
[18] 张长平,崔向丽,王咏梅.药物性肝损伤200例临床分析.肝脏,2014,19: 483-485.
[19] Russo MW, Jacobson IM. How to use statins in patients with chronic liver disease. Cleve Clin J Med,2004,71:58-62.